Price Target Changed • May 20
Price target decreased by 9.1% to €5.50 Down from €6.05, the current price target is an average from 3 analysts. New target price is 87% above last closing price of €2.94. Stock is up 32% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.54 last year. Breakeven Date Change • May 20
No longer forecast to breakeven The 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.49m in 2028. New consensus forecast suggests the company will make a loss of €5.44m in 2028. Annonce • May 12
BRAIN Biotech AG to Report Fiscal Year 2026 Results on Jan 14, 2027 BRAIN Biotech AG announced that they will report fiscal year 2026 results on Jan 14, 2027 Annonce • Feb 02
BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026 BRAIN Biotech AG, Annual General Meeting, Mar 11, 2026, at 10:00 W. Europe Standard Time. Annonce • Jan 17
BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026 BRAIN Biotech AG provided revenue guidance for the year 2025/2026. For the financial year, BRAIN Biotech expects a small increase in group revenues vs. the previous financial year. Annonce • May 21
BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. BRAIN Biotech AG (XTRA:BNN) acquired remaining minority stake in Breatec B.V. on May 20, 2025. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG.
BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining minority stake in Breatec B.V. on May 20, 2025. Annonce • Feb 06
BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025 BRAIN Biotech AG, Annual General Meeting, Mar 18, 2025, at 10:00 W. Europe Standard Time. Annonce • Jan 19
BRAIN Biotech AG to Report Q3, 2025 Results on Aug 28, 2025 BRAIN Biotech AG announced that they will report Q3, 2025 results on Aug 28, 2025 Breakeven Date Change • Dec 30
Forecast to breakeven in 2027 The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.03m in 2027. Average annual earnings growth of 68% is required to achieve expected profit on schedule. Price Target Changed • Nov 14
Price target decreased by 26% to €6.30 Down from €8.48, the current price target is an average from 4 analysts. New target price is 120% above last closing price of €2.86. Stock is down 27% over the past year. The company is forecast to post a net loss per share of €0.27 next year compared to a net loss per share of €0.38 last year. Breakeven Date Change • Nov 14
Forecast breakeven date pushed back to 2027 The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of €8.80m in 2027. Average annual earnings growth of 67% is required to achieve expected profit on schedule. New Risk • Sep 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (€32.1m market cap, or US$35.9m). Price Target Changed • Aug 31
Price target decreased by 20% to €8.38 Down from €10.50, the current price target is an average from 4 analysts. New target price is 396% above last closing price of €1.69. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.38 last year. Reported Earnings • Aug 30
Third quarter 2024 earnings released: €0.12 loss per share (vs €0.084 loss in 3Q 2023) Third quarter 2024 results: €0.12 loss per share (further deteriorated from €0.084 loss in 3Q 2023). Revenue: €13.6m (flat on 3Q 2023). Net loss: €2.57m (loss widened 39% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Annonce • Aug 30
BRAIN Biotech AG to Report First Half, 2025 Results on May 28, 2025 BRAIN Biotech AG announced that they will report first half, 2025 results on May 28, 2025 Price Target Changed • Aug 28
Price target decreased by 8.9% to €10.00 Down from €10.98, the current price target is an average from 4 analysts. New target price is 502% above last closing price of €1.66. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.38 last year. Reported Earnings • May 29
Second quarter 2024 earnings released: €0.088 loss per share (vs €0.10 loss in 2Q 2023) Second quarter 2024 results: €0.088 loss per share (improved from €0.10 loss in 2Q 2023). Revenue: €14.8m (up 8.5% from 2Q 2023). Net loss: €1.92m (loss narrowed 15% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Annonce • May 07
BRAIN Biotech AG to Report Q1, 2025 Results on Feb 26, 2025 BRAIN Biotech AG announced that they will report Q1, 2025 results on Feb 26, 2025 Buy Or Sell Opportunity • Mar 26
Now 22% undervalued Over the last 90 days, the stock has risen 2.0% to €3.54. The fair value is estimated to be €4.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 2.7%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 81% in the next 2 years. Annonce • Mar 22
BRAIN Biotech AG to Report Fiscal Year 2024 Results on Jan 15, 2025 BRAIN Biotech AG announced that they will report fiscal year 2024 results on Jan 15, 2025 Breakeven Date Change • Mar 03
Forecast breakeven date pushed back to 2026 The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 37% per year to 2025. The company is expected to make a profit of €4.27m in 2026. Average annual earnings growth of 65% is required to achieve expected profit on schedule. Reported Earnings • Feb 29
First quarter 2024 earnings released: €0.12 loss per share (vs €0.12 loss in 1Q 2023) First quarter 2024 results: €0.12 loss per share (further deteriorated from €0.12 loss in 1Q 2023). Revenue: €13.1m (down 6.3% from 1Q 2023). Net loss: €2.65m (loss widened 4.5% from 1Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 17
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: €0.38 loss per share (further deteriorated from €0.30 loss in FY 2022). Revenue: €57.0m (up 13% from FY 2022). Net loss: €8.28m (loss widened 26% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Sep 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Price Target Changed • Sep 05
Price target decreased by 8.2% to €11.23 Down from €12.23, the current price target is an average from 4 analysts. New target price is 148% above last closing price of €4.53. Stock is down 32% over the past year. The company is forecast to post a net loss per share of €0.41 next year compared to a net loss per share of €0.30 last year. Annonce • Sep 03
BRAIN Biotech AG to Report Nine Months, 2024 Results on Aug 29, 2024 BRAIN Biotech AG announced that they will report nine months, 2024 results on Aug 29, 2024 Reported Earnings • Sep 01
Third quarter 2023 earnings released: €0.084 loss per share (vs €0.12 loss in 3Q 2022) Third quarter 2023 results: €0.084 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €13.8m (up 5.7% from 3Q 2022). Net loss: €1.84m (loss narrowed 30% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 14
Forecast to breakeven in 2025 The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2024. The company is expected to make a profit of €1.68m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule. Annonce • Aug 08
BRAIN Biotech AG to Report First Half, 2024 Results on May 28, 2024 BRAIN Biotech AG announced that they will report first half, 2024 results on May 28, 2024 New Risk • Jul 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Share price has been volatile over the past 3 months (6.9% average weekly change). New Risk • Jun 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.9m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Market cap is less than US$100m (€90.9m market cap, or US$99.1m). Reported Earnings • May 30
Second quarter 2023 earnings released: €0.10 loss per share (vs €0.073 loss in 2Q 2022) Second quarter 2023 results: €0.10 loss per share (further deteriorated from €0.073 loss in 2Q 2022). Revenue: €13.8m (up 4.5% from 2Q 2022). Net loss: €2.27m (loss widened 42% from 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Annonce • May 25
BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited. BRAIN Biotech AG (XTRA:BNN) acquired remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. The minority stake purchases have been financed from existing BRAIN Biotech's cash reserves and from new debt.BRAIN Biotech AG (XTRA:BNN) completed the acquisition of remaining 17.8% stake in Biocatalysts Limited on May 24, 2023. Reported Earnings • Mar 03
First quarter 2023 earnings released: €0.12 loss per share (vs €0.11 loss in 1Q 2022) First quarter 2023 results: €0.12 loss per share (further deteriorated from €0.11 loss in 1Q 2022). Revenue: €14.1m (up 36% from 1Q 2022). Net loss: €2.53m (loss widened 7.3% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 03
Forecast breakeven date moved forward to 2024 The 4 analysts covering BRAIN Biotech previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €650.0k in 2024. Average annual earnings growth of 104% is required to achieve expected profit on schedule. Annonce • Jan 11
BRAIN Biotech AG to Report Fiscal Year 2022 Results on Jan 16, 2023 BRAIN Biotech AG announced that they will report fiscal year 2022 results on Jan 16, 2023 Annonce • Jan 10
BRAIN Biotech AG Announces Executive Changes BRAIN Biotech AG announced the appointments of two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international BRAIN Group. Following the announcement in October 2022, to establish an independent division for BRAIN Biotech AG's proprietary CRISPR technology announced that Dr. Alexander Pelzer will succeed Dr. Michael Krohn as Head of Research & Development. Dr. Krohn will now fully focus on his new leadership role with Akribion Genomics. Dr. Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr. Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path. In addition, Dr. Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr. Langer was one of the first employees at BRAIN Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions. Breakeven Date Change • Nov 17
Forecast to breakeven in 2025 The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Annonce • Nov 04
BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023 BRAIN Biotech AG, Annual General Meeting, Mar 08, 2023. Price Target Changed • Oct 20
Price target decreased to €12.91 Down from €14.29, the current price target is an average from 4 analysts. New target price is 158% above last closing price of €5.00. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €0.32 next year compared to a net loss per share of €0.25 last year. Price Target Changed • Oct 05
Price target increased to €17.50 Up from €15.30, the current price target is an average from 3 analysts. New target price is 262% above last closing price of €4.83. Stock is down 52% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €0.25 last year. Breakeven Date Change • Oct 01
Forecast to breakeven in 2025 The 4 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.08m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule. Reported Earnings • Jun 05
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: €0.073 loss per share (down from €0.10 profit in 2Q 2021). Revenue: €13.2m (up 31% from 2Q 2021). Net loss: €1.60m (down 177% from profit in 2Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 32%. Over the next year, revenue is forecast to grow 20%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jun 01
No longer forecast to breakeven The 4 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €667.0k in 2024. New consensus forecast suggests the company will make a loss of €83.9k in 2024. Reported Earnings • Feb 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: €0.11 loss per share (up from €0.19 loss in 1Q 2021). Revenue: €10.7m (up 29% from 1Q 2021). Net loss: €2.36m (loss narrowed 30% from 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 15%, compared to a 2.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 04
Forecast to breakeven in 2024 The 5 analysts covering BRAIN Biotech expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 19% per year to 2023. The company is expected to make a profit of €2.06m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Reported Earnings • Jan 20
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • Jan 20
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: €0.25 loss per share (up from €0.52 loss in FY 2020). Revenue: €40.7m (up 4.2% from FY 2020). Net loss: €4.97m (loss narrowed 49% from FY 2020). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 32%. Over the next year, revenue is forecast to grow 7.1%, compared to a 5.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jan 17
No longer forecast to breakeven The 5 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.43m in 2024. New consensus forecast suggests the company will make a loss of €3.21m in 2024. Reported Earnings • Sep 01
Third quarter 2021 earnings released: €0.10 loss per share (vs €0.096 loss in 3Q 2020) The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: €10.1m (up 3.6% from 3Q 2020). Net loss: €2.03m (loss widened 16% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 18
Price target increased to €16.22 Up from €14.22, the current price target is an average from 6 analysts. New target price is 53% above last closing price of €10.60. Stock is up 27% over the past year. Breakeven Date Change • Jul 15
No longer forecast to breakeven The 6 analysts covering BRAIN Biotech no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.12m in 2023. New consensus forecast suggests the company will make a loss of €701.5k in 2023. Reported Earnings • May 29
Second quarter 2021 earnings released: EPS €0.10 (vs €0.14 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €11.2m (up 14% from 2Q 2020). Net income: €2.07m (up €4.56m from 2Q 2020). Profit margin: 18% (up from net loss in 2Q 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 28
First quarter 2021 earnings released: €0.19 loss per share (vs €0.13 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €8.41m (down 20% from 1Q 2020). Net loss: €3.36m (loss widened 49% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 16
New 90-day high: €9.66 The company is up 32% from its price of €7.32 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. Analyst Estimate Surprise Post Earnings • Jan 20
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 8.8%, compared to a 4.0% growth forecast for the Chemicals industry in Germany. Analyst Estimate Surprise Post Earnings • Jan 18
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) exceeded analyst estimates by 37%. Over the next year, revenue is forecast to grow 12%, compared to a 4.0% growth forecast for the Chemicals industry in Germany. Reported Earnings • Jan 16
Full year 2020 earnings released: €0.52 loss per share The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €39.1m (down 2.5% from FY 2019). Net loss: €9.68m (loss narrowed 13% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Jan 14
New 90-day high: €9.26 The company is up 22% from its price of €7.60 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.85 per share. Is New 90 Day High Low • Dec 23
New 90-day high: €8.84 The company is up 21% from its price of €7.32 on 23 September 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.53 per share. Is New 90 Day High Low • Oct 30
New 90-day low: €6.80 The company is down 16% from its price of €8.08 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.89 per share. Price Target Changed • Sep 24
Price target lowered to €12.77 Down from €16.17, the current price target is an average from 5 analysts. The new target price is 74% above the current share price of €7.32. As of last close, the stock is down 36% over the past year.